Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 13/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 13/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 13/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 13/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 13/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 13/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 13/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TYMS | P04818 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15173463 | 0.78 | GRIN2D (0.51) | ALDH1A1GLATSHRGRIN2DGRIN3B | |
| SCHEMBL3649106 | 0.78 | GRIN2D (0.51) | ALDH1A1GLAGRIN2DGRIN3BGRIN1 | |
| SCHEMBL3224636 | 0.78 | ALDH1A1 (0.49) | ALDH1A1GLAGRIN2DGRIN3BGRIN1 | |
| SCHEMBL28457520 | 0.75 | GRIN2D (0.54) | ALDH1A1GLATSHRGRIN2DGRIN3B | |
| SCHEMBL7016425 | 0.75 | GRIN2D (0.54) | ALDH1A1GLATSHRGRIN2DGRIN3B | |
| SCHEMBL16914015 | 0.74 | ALDH1A1 (0.45) | ALDH1A1GLAGRIN2DGRIN3BGRIN1 | |
| SCHEMBL5250855 | 0.70 | ALDH1A1 (0.44) | ALDH1A1GLATSHRGRIN2DGRIN3B | |
| SCHEMBL2639506 | 0.68 | GRIN2D (0.72) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL30729476 | 0.67 | PTGER4 (0.50) | ALDH1A1TSHRGRIN2DGRIN3BGRIN1 | |
| SCHEMBL28089909 | 0.67 | ALDH1A1 (0.40) | ALDH1A1GLATSHRGRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018086604-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATIONS THEREOF | 山东罗欣药业集团股份有限公司 | 2018-05-17 | — | — | WO | disclosed |
| WO-2010026075-A1 | PYRIDINE DERIVATIVES AS INHIBITORS OF HIV-I REVERSE TRANSCRIPTASE | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-11 | — | — | WO | disclosed |
| US-20100056535-A1 | Inhibitors of HIV-1 reverse transcriptase | ROCHE PALO ALTO LLC | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056535-A1 | Inhibitors of HIV-1 reverse transcriptase | QTRT1, NQO2, QTRT2 | ALDH1A1 301/4885GLA 1551/4885TSHR 3003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.